Liberate Bio
Liberate Bio is pioneering next-generation genetic medicine delivery systems with its RAPTOR™ platform, aiming to enable extrahepatic delivery at industrial speed. Their mission is to break the barriers of genetic medicine, unlocking the full potential of mRNA, CRISPR, and gene editing technologies by delivering genetic medicines anywhere in the body. The company focuses on innovative solutions such as direct testing in non-human primates, AI-driven chemistry for nanoparticle design, and developing therapies like CAR-M for solid tumors. Their vision is to deliver genetic medicines that transcend liver-based limitations, transforming patient outcomes worldwide.
Industries
Nr. of Employees
small (1-50)
Liberate Bio
Products
Platform for extrahepatic nucleic acid delivery
A platform combining high-throughput pooled in vivo screening, AI-driven lipid design, and preclinical NHP testing to enable targeted delivery of nucleic acid medicines outside the liver.
In vivo CAR-M therapeutic program (preclinical)
An in vivo therapeutic approach that delivers mRNA to monocyte progenitors in bone marrow to program tumor-killing macrophages as a potential treatment for solid tumors.
Platform for extrahepatic nucleic acid delivery
A platform combining high-throughput pooled in vivo screening, AI-driven lipid design, and preclinical NHP testing to enable targeted delivery of nucleic acid medicines outside the liver.
In vivo CAR-M therapeutic program (preclinical)
An in vivo therapeutic approach that delivers mRNA to monocyte progenitors in bone marrow to program tumor-killing macrophages as a potential treatment for solid tumors.
Services
Preclinical pooled in vivo screening service
Pooled RNA-barcoded screening of nanoparticle formulations in vivo to generate multi-organ biodistribution and expression datasets for formulation selection.
Collaborative development partnerships
Partnership engagements to co-develop delivery platforms and therapeutic programs, including access to platform capabilities and shared discovery efforts.
Preclinical pooled in vivo screening service
Pooled RNA-barcoded screening of nanoparticle formulations in vivo to generate multi-organ biodistribution and expression datasets for formulation selection.
Collaborative development partnerships
Partnership engagements to co-develop delivery platforms and therapeutic programs, including access to platform capabilities and shared discovery efforts.
Expertise Areas
- Targeted extrahepatic nucleic acid delivery
- Lipid nanoparticle discovery and optimization
- In vivo preclinical evaluation in non-human primates
- AI/ML-driven medicinal chemistry for delivery materials
Key Technologies
- Lipid nanoparticles (LNPs)
- RNA barcoding for pooled in vivo screens
- Machine learning / AI-driven chemistry
- Non-human primate in vivo models